🇺🇸 FDA
Patent

US 10752639

Bridged bicyclic inhibitors of menin-MLL and methods of use

granted A61KA61K31/445A61P

Quick answer

US patent 10752639 (Bridged bicyclic inhibitors of menin-MLL and methods of use) held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Grant date
Tue Aug 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/445, A61P, A61P35/02